Use of the Barthel Index and Modified Rankin Scale in acute stroke trials

Stroke

Volumn 30, Issue 8, 1999, Pages 1538-1541

  Sulter, Geert ^a   Steen, Christel ^a   De Keyser, Jacques ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Disability evaluation; Outcome; Stroke trials

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; DANAPAROID; EBSELEN; FIBRINOLYTIC AGENT; FLUNARIZINE; LOW MOLECULAR WEIGHT HEPARIN; LUBELUZOLE; NADROPARIN; NEUROPROTECTIVE AGENT; PIRACETAM; STREPTOKINASE; TIRILAZAD;

ACUTE DISEASE; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISABILITY; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RATING SCALE; STROKE; TREATMENT OUTCOME;

EID: 0032796473     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.8.1538     Document Type: Article

References (22)

1. Mahoney F. Barthel D. Functional evaluation: the Barthel Index. Md Med J. 1965;14:61-65.
2. Granger CV, Devis LS, Peters MC, Sherwood CC, Barrett JE. Stroke rehabilitation: analysis of repeated Barthel Index measures. Arch Phys Med Rehabil. 1979;60:14-17.
3. D'Olhaberriague L, Litvan I, Mitsias P, Mansbach HH. A reappraisal of reliability and validity studies in stroke. Stroke. 1996;27:2331-2336.
4. van Swieten JC, Koudstaal PJ, Visser MC, Scheuten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
5. Franke CL, Palm R, Dalby M, Schoonderwaldt HC, Hantson L, Eriksson B, Lang-Jenssen L, Smakman J. Flunarizine in Stroke Treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol Scand. 1996;93:56-60.
6. De Deyn P, De Reuck J Deberdt W, Vlietinck R, Orgogozo JM, for the Members of the Piracetam in Acute Stroke Study (PASS) Group. Treatment of acute ischemic stroke with piracetam. Stroke. 1997;28: 2347-2352.
7. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke. 1996;27:1453-1458.
8. Grotta J, for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. Stroke. 1997;28: 2338-2346.
9. Diener HC, for the European and Australian Lubeluzole Ischemic Stroke Study Group. Multinational randomised controlled trial of lubeluzole in acute ischemic stroke. Cerebrovasc Dis. 1998;8:172-181.
10. Davis SM, Albers GW, Diener HC, Lees KR, Norris J. Termination of acute stroke studies involving selfotel treatment. Lancet. 1997;349:32. Letter.
11. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H, for the Ebselen Study Group. Ebselen in Acute Ischemic Stroke: a placebo-controlled, double-blind clinical trial. Stroke. 1998;29: 12-17.
12. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A, Woo J. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333:1588-1593.
13. The Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, Org 10172 (Danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA. 1998;279:1265-1272.
14. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne M-H, Hennerici M, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
15. Hacke W, Kaste M, Fiechi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P, for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
17. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145-150.
18. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet. 1995;346:1509-1514.
19. Donnan GA, Davis SM, Chambers BR, for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA. 1996;276:961-966.
20. Kay R, Wong KS, Perez G, Woo J. Dichotomizing stroke outcomes based on self-reported dependency. Neurology. 1997;49:1694-1696.
21. Dennis M, Wellwood I, Warlow C. Are simple questions a valid measure of outcome after stroke? Cerebrovasc Dis. 1997;7:22-27.
22. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.